{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:31:16Z","timestamp":1785803476999,"version":"3.56.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","sempedneurjnl.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.spen.2017.08.007","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T08:00:35Z","timestamp":1503475235000},"page":"189-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["The Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children"],"prefix":"10.1016","volume":"24","author":[{"given":"Rinze","family":"Neuteboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Wilbur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Van Pelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spen.2017.08.007_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1212\/01.wnl.0000339482.84392.bd","article-title":"Incidence of acquired demyelination of the CNS in Canadian children","volume":"72","author":"Banwell","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00415-012-6441-6","article-title":"Incidence of acquired demyelinating syndromes of the CNS in Dutch children: A nationwide study","volume":"259","author":"Ketelslegers","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e31822facdd","article-title":"Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children","volume":"77","author":"Langer-Gould","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: Revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib5","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib6","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1212\/WNL.0000000000002881","article-title":"Pediatric acquired CNS demyelinating syndromes: Features associated with multiple sclerosis","volume":"87","author":"Hintzen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1474-4422(14)70093-6","article-title":"Multiple sclerosis in children: An update on clinical diagnosis, therapeutic strategies, and research","volume":"13","author":"Waldman","year":"2014","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.spen.2017.08.007_bib8","first-page":"36","article-title":"Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: A prospective national cohort study","volume":"10","author":"Banwell","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1352458512445944","article-title":"Paediatric acquired demyelinating syndromes: Incidence, clinical and magnetic resonance imaging features","volume":"19","author":"Absoud","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/1352458510390068","article-title":"Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children","volume":"17","author":"Ketelslegers","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejpn.2016.08.014","article-title":"Evolution of MRI abnormalities in paediatric acute disseminated encephalomyelitis","volume":"21","author":"Wong","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib12","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/1352458512466317","article-title":"Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients","volume":"19","author":"Huppke","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000284600.80782.d5","article-title":"Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders","volume":"70","author":"Banwell","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1212\/WNL.0000000000002283","article-title":"Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report","volume":"86","author":"Chitnis","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1136\/jnnp-2013-306850","article-title":"Application of the 2012 revised diagnostic definitions for paediatric multiple sclerosis and immune-mediated central nervous system demyelination disorders","volume":"85","author":"Van Pelt","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.spen.2017.08.007_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ana.23575","article-title":"2010 McDonald criteria for diagnosing pediatric multiple sclerosis","volume":"72","author":"Sadaka","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib18","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1212\/NXI.0000000000000309","article-title":"B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis","volume":"4","author":"Schwarz","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.spen.2017.08.007_bib19","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1212\/WNL.0000000000001066","article-title":"Epitope spreading as an early pathogenic event in pediatric multiple sclerosis","volume":"83","author":"Quintana","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrn784","article-title":"New concepts in the immunopathogenesis of multiple sclerosis","volume":"3","author":"Hemmer","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.spen.2017.08.007_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2016.04.015","article-title":"T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis","volume":"297","author":"Cala","year":"2016","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.spen.2017.08.007_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jneuroim.2006.03.020","article-title":"CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis","volume":"175","author":"Ishizu","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.spen.2017.08.007_bib23","doi-asserted-by":"crossref","first-page":"e0161656","DOI":"10.1371\/journal.pone.0161656","article-title":"Utility of CSF cytokine\/chemokines as markers of active intrathecal inflammation: Comparison of demyelinating, anti-NMDAR and enteroviral encephalitis","volume":"11","author":"Kothur","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.spen.2017.08.007_bib24","doi-asserted-by":"crossref","first-page":"e0149411","DOI":"10.1371\/journal.pone.0149411","article-title":"B-cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.spen.2017.08.007_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Pr\u00f6bstel","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib26","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2017.08.007_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.autrev.2011.05.007","article-title":"Genetic background of multiple sclerosis","volume":"11","author":"Sadovnick","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.spen.2017.08.007_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0301-0082(95)80008-V","article-title":"Migrant studies in multiple sclerosis","volume":"47","author":"Gale","year":"1995","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.spen.2017.08.007_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12883-015-0394-1","article-title":"Latitude, sun exposure and vitamin D supplementation: Associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis","volume":"15","author":"Jelinek","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib30","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.cell.2015.08.025","article-title":"Melatonin contributes to the seasonality of multiple sclerosis relapses","volume":"162","author":"Farez","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.spen.2017.08.007_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1352458515595876","article-title":"Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination","volume":"22","author":"Makhani","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00415-009-0120-2","article-title":"Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis","volume":"256","author":"Pittas","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2013.08.011","article-title":"Physical trauma and risk of multiple sclerosis: A systematic review and meta-analysis of observational studies","volume":"336","author":"Lunny","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.spen.2017.08.007_bib34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/1352458513483889","article-title":"Childhood body mass index and multiple sclerosis risk: A long-term cohort study","volume":"19","author":"Munger","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/WNL.0b013e31828154f3","article-title":"Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome","volume":"80","author":"Langer-Gould","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1352458515609431","article-title":"Implications of dietary salt intake for multiple sclerosis pathogenesis","volume":"22","author":"Hucke","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib37","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib38","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/01.WNL.0000158474.24191.BC","article-title":"Cognitive functioning in children and adolescents with multiple sclerosis","volume":"64","author":"MacAllister","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib39","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1212\/WNL.0000000000000885","article-title":"Neuropsychological features in childhood and juvenile multiple sclerosis: Five-year follow-up","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0883073812464816","article-title":"Cognitive impairment occurs in children and adolescents with multiple sclerosis:Results from a United States network","volume":"28","author":"Julian","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib41","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1212\/01.wnl.0000312276.23177.fa","article-title":"Cognitive and psychosocial features of childhood and juvenile MS","volume":"70","author":"Amato","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib42","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/WNL.0b013e3181f4d821","article-title":"Cognitive and psychosocial features in childhood and juvenile MS: Two-year follow-up","volume":"75","author":"Amato","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/1352458515588781","article-title":"Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis","volume":"22","author":"Baruch","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib44","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/1352458509345902","article-title":"Fatigue and quality of life in pediatric multiple sclerosis","volume":"15","author":"MacAllister","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458511420846","article-title":"Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis","volume":"18","author":"Goretti","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejpn.2009.09.004","article-title":"Fatigue and depression in children with multiple sclerosis and monophasic variants","volume":"14","author":"Ketelslegers","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pediatrneurol.2010.03.007","article-title":"Health-related quality of life is reduced in pediatric multiple sclerosis","volume":"43","author":"Mowry","year":"2010","journal-title":"Pediatric Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib48","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1212\/WNL.59.8.1224","article-title":"Acute disseminated encephalomyelitis: A long-term follow-up study of 84 pediatric patients","volume":"59","author":"Tenembaum","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib49","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pediatrneurol.2013.12.006","article-title":"Long-term neurocognitive outcome and quality of life in pediatric acute disseminated encephalomyelitis","volume":"50","author":"Suppiej","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pediatrneurol.2016.01.003","article-title":"Long-term neurocognitive, psychosocial, and magnetic resonance imaging outcomes in pediatric-onset acute disseminated encephalomyelitis","volume":"57","author":"Beatty","year":"2016","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pediatrneurol.2004.03.008","article-title":"Neuropsychological outcome after acute disseminated encephalomyelitis: Impact of age at illness onset","volume":"31","author":"Jacobs","year":"2004","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib52","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0883073810395141","article-title":"Management of pediatric central nervous system demyelinating disorder: Consensus of United States neurologists","volume":"26","author":"Waldman","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib53","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dmcn.13159","article-title":"Intravenous immunoglobulin in paediatric neurology: Safety, adherence to guidelines, and long-term outcome","volume":"58","author":"Nosadini","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib54","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/0883073814545883","article-title":"Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination","volume":"30","author":"Bigi","year":"2015","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archneurol.2010.325","article-title":"Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis","volume":"68","author":"Yeh","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458511430704","article-title":"Consensus statement: Evaluation of new and existing therapeutics for pediatric multiple sclerosis","volume":"18","author":"Chitnis","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib57","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/1352458516644676","article-title":"Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-NO","volume":"22","author":"Naismith","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib58","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/1352458516650737","article-title":"Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES","volume":"22","author":"Giovannoni","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib59","first-page":"1277","article-title":"The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"45","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib60","first-page":"1498","article-title":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2017.08.007_bib61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib62","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10072-009-0083-1","article-title":"Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: The Italian experience","volume":"30","author":"Ghezzi","year":"2009","journal-title":"Neurol Sci"},{"key":"10.1016\/j.spen.2017.08.007_bib64","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0883073813488828","article-title":"Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: A retrospective study","volume":"28","author":"Tenembaum","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib65","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","volume":"49","author":"Comi","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib66","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/1352458509358088","article-title":"Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate","volume":"16","author":"Ford","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib67","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2017.08.007_bib68","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-2003-41274","article-title":"Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis","volume":"34","author":"Kornek","year":"2003","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.spen.2017.08.007_bib70","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0b013e3182a2cc4a","article-title":"Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS","volume":"81","author":"Makhani","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib71","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib72","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib73","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib74","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1212\/WNL.0000000000001556","article-title":"Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod","volume":"84","author":"Tully","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib75","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s40264-016-0461-6","article-title":"Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: A comprehensive review of current evidence and future needs","volume":"39","author":"D'Amico","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.spen.2017.08.007_bib76","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pediatrneurol.2015.03.024","article-title":"Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than age 18 years","volume":"53","author":"Fragoso","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib77","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2016.01.010","article-title":"Oral dimethyl fumarate in children with multiple sclerosis: A dual-center study","volume":"57","author":"Makhani","year":"2016","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib79","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib80","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib81","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib82","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib83","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib84","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12883-015-0433-y","article-title":"Natalizumab in the pediatric MS population: Results of the Italian registry","volume":"15","author":"Ghezzi","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib85","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib86","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pediatrneurol.2014.02.007","article-title":"Rituximab use in pediatric central demyelinating disease","volume":"51","author":"Beres","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib87","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00415-015-7979-x","article-title":"Rituximab in paediatric onset multiple sclerosis: A case series","volume":"263","author":"Salzer","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib88","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib89","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1191\/1352458505ms1210oa","article-title":"A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta","volume":"11","author":"Smith","year":"2005","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib90","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/WNL.0b013e3181a8164c","article-title":"Cyclophosphamide therapy in pediatric multiple sclerosis","volume":"72","author":"Makhani","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib91","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2017.08.007_bib92","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib93","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2017.08.007_bib94","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2011.581","article-title":"Daclizumab use in patients with pediatric multiple sclerosis","volume":"69","author":"Gorman","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib95","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2017.08.007_bib96","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1517\/14712598.2016.1158809","article-title":"Recent advances in monoclonal antibody therapies for multiple sclerosis","volume":"16","author":"Wootla","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.spen.2017.08.007_bib97","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nn.2172","article-title":"Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency","volume":"11","author":"Shen","year":"2008","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.spen.2017.08.007_bib98","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.97.12.6820","article-title":"Human monoclonal antibodies promote remyelination of spinal cord lesions in a model of multiple sclerosis","volume":"97","author":"Warrington","year":"2000","journal-title":"PNAS"},{"key":"10.1016\/j.spen.2017.08.007_bib99","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/jnen\/63.5.461","article-title":"Neuron-binding human monoclonal antibodies support central nervous system neurite extension","volume":"63","author":"Warrington","year":"2004","journal-title":"J Neuropath Exp Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2017.08.007_bib101","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: A multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib102","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib103","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib104","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0883073810381445","article-title":"Efficacy and safety of rituximab in pediatric neuromyelitis optica","volume":"26","author":"Mahmood","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2017.08.007_bib105","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1212\/NXI.0000000000000188","article-title":"Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder","author":"Nosadini","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.spen.2017.08.007_bib106","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2017.08.007_bib107","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909117301031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909117301031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T10:58:45Z","timestamp":1535453925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909117301031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1071909117301031"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2017.08.007","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spen.2017.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}